Cure Hepatitis C Act of 2025 Introduced in Senate, ASAM Issues Support

In a letter to US Senators Bill Cassidy (LA) and Chris Van Hollen (MD), ASAM expressed its strong support for S. 1941- the Cure Hepatitis C Act of 2025, which the Senators introduced in June. The legislation aims to establish an innovative purchasing model and support a public health infrastructure for a test-to-treat hepatitis C virus (HCV) program, thereby improving patient access to comprehensive treatment.

HCV is the most common bloodborne infection associated with drug use. Curative direct-acting antiviral (DAA) therapies can reduce disease burden and transmission, but high costs and the current structure of health care financing systems can hinder access. 

To solve this, the Cure Hepatitis C Act of 2025 would allow states to commit to a “subscription fee” to access an unlimited supply of DAA medications for a period of time rather than pay a fixed price per dose or course of treatment. Ultimately, it would lower the cost of DAA for those states. ASAM's Public Policy Statement Hepatitis C Virus, Substance Use, and Addiction recommends that states explore using innovative strategies like subscription models to expand access to evidence-based HCV treatments.

Read ASAM's full letter of support here.